U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07437404) titled 'Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.' on Feb. 09.
Brief Summary: This is an Open Label, Uncontrolled Study to Evaluate the the Safety and Efficacy of SCT800 for Prophylaxis Treatment in Severe Previously Untreated Hemophilia Patients.
Study Start Date: April 26, 2024
Study Type: INTERVENTIONAL
Condition:
Haemophilia A
Intervention:
DRUG: SCT800 prophylaxis and treatment for bleeding events
For prophylaxis, 15-50 IU/kg SCT800 is intravenously. For control of bleeding events(BE), 10-20 IU/kg for mild BE, 15 -30IU/kg for moderate BE, 30-50IU/kg for severe BE.
Recruitment ...